VERAXA Biotech (NASDAQ: VRXA) has completed its business combination and commenced trading on Nasdaq in June 2026, a move that positions the company to accelerate its oncology pipeline and forge industrial partnerships for its technology platforms and products. The development was highlighted in a first-half progress report from Xlife Sciences AG (SIX: XLS), which said VERAXA secured a financing base to support its next development steps and remains an important part of its portfolio strategy. For investors tracking the biotech sector, the listing provides a new public-market vehicle focused on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. More details are available in the full report at https://ibn.fm/LwLwP.
Xlife Sciences also reported operational and scientific progress across its portfolio during the first half of 2026, including developments at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI, and inflamed pharma. The portfolio comprises 416 patents and patent applications, including 216 granted intellectual property rights—a significant intellectual property estate that underscores the depth of the company’s research and development efforts. For the second half of 2026, Xlife Sciences said it will continue supporting VERAXA in establishing industry partnerships while pursuing commercialization and further development across its portfolio. The company’s broader mission is to bridge research and development to healthcare markets by incubating and accelerating promising projects from universities and other research institutions. Additional information about Xlife Sciences is available at www.xlifesciences.ch.
VERAXA, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is building a premier engine for the discovery and development of next-generation antibody-based therapeutics. Its proprietary BiTAC(R) format is a registered trademark of VERAXA Biotech GmbH. The company is advancing a pipeline of ADCs and BiTAC formats into clinical development and beyond, guided by rigorous quality-by-design principles. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
The announcement matters because it signals the maturation of a Swiss biotech incubator’s portfolio into a publicly traded entity with a dedicated oncology focus. Xlife Sciences, which takes carefully selected projects in technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to the next stage, now has a Nasdaq-listed vehicle in VERAXA. That could enhance access to capital and industry partnerships, potentially accelerating the path from research to market for treatments addressing high unmet medical needs.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, disseminated the update. It is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit BioMedWire.
